Emergent Biosolutions (0IGA) Financial Statements
Emergent Biosolutions Financial Overview
Emergent Biosolutions's market cap is currently $349.17M. The company's EPS TTM is $-3.44; its P/E ratio is -1.98; Emergent Biosolutions is estimated to report earnings on November 2, 2026, and the estimated EPS forecast is $-0.39. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 742.90M | $ 1.04B | $ 1.05B | $ 1.12B | $ 1.77B |
| Gross Profit | $ 350.60M | $ 375.40M | $ 360.00M | $ 473.00M | $ 793.20M |
| Operating Income | $ 110.20M | $ -108.70M | $ -726.40M | $ -170.00M | $ 341.40M |
| EBITDA | $ 237.90M | $ 56.60M | $ -43.00M | $ 34.00M | $ 509.80M |
| Net Income | $ 52.60M | $ -190.60M | $ -760.50M | $ -211.60M | $ 219.50M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 205.40M | $ 99.50M | $ 111.70M | $ 642.60M | $ 576.30M |
| Total Assets | $ 1.32B | $ 1.39B | $ 1.82B | $ 3.17B | $ 2.96B |
| Total Debt | $ 572.10M | $ 676.10M | $ 860.20M | $ 1.43B | $ 871.00M |
| Net Debt | $ 366.70M | $ 576.60M | $ 748.50M | $ 783.80M | $ 294.70M |
| Total Liabilities | $ 796.00M | $ 906.90M | $ 1.17B | $ 1.78B | $ 1.35B |
| Stockholders' Equity | $ 522.60M | $ 482.80M | $ 649.30M | $ 1.39B | $ 1.61B |
| Cash Flow | |||||
| Free Cash Flow | $ 156.80M | $ 35.80M | $ -257.90M | $ -149.90M | $ 96.10M |
| Operating Cash Flow | $ 170.60M | $ 58.70M | $ -206.30M | $ -34.10M | $ 321.10M |
| Investing Cash Flow | $ 69.40M | $ 125.20M | $ 212.30M | $ -381.30M | $ -225.00M |
| Financing Cash Flow | $ -136.60M | $ -190.00M | $ -535.70M | $ 481.20M | $ -141.00M |
Currency in USD